ThromboGenics
ThromboGenics announced its latest developments
Published in Healthcare Mergers, Acquisitions and Ventures Week, May 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at ThromboGenics.
Report 1: ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS:BINV) announced today that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of the novel anticoagulant, TB-402. TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. The project is being developed within the framework of the alliance between ThromboGenics and BioInvent.
The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- 3D Systems Corporation
3D Systems Recruits Chief Financial Officer - AARP
Calls for Rx Marketing Reform to Lower Cost of Prescription Drugs - ABB
ABB Announces PAT Solution for the Life Sciences Industry - ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Announces Exercise of Over-Allotment by Underwriters - Aceto Corporation
Aceto Schedules Third Quarter Financial Results News Release and Conference Call - Acne Vulgaris
Acne Sufferers Trading Off Youthful Skin for Treating Acne - Two Linked Conditions - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
